
David Margel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2692686/publications.pdf Version: 2024-02-01



DAVID MARCEL

#	Article	IF	CITATIONS
1	Guest Editorial: In the Genetic Era Family History is Just Not Enough!!!. Journal of Urology, 2022, , 101097JU000000000002761.	0.2	0
2	Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist. Prostate Cancer and Prostatic Diseases, 2021, 24, 177-185.	2.0	11
3	Diffusion Is Directional: Innovative Diffusion Tensor Imaging to Improve Prostate Cancer Detection. Diagnostics, 2021, 11, 563.	1.3	5
4	Indications for prostate multiparametric magnetic resonance imaging: changes over 7Âyears in a single referral centre. BJU International, 2021, 128, 165-167.	1.3	0
5	Role of Metabolic Syndrome in Prostate Cancer Development. European Urology Focus, 2021, 7, 508-512.	1.6	5
6	Diagnostic Performance of ⁶⁸ Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer. Radiology, 2021, 301, 379-386.	3.6	28
7	Reply by Authors. Journal of Urology, 2021, 206, 959-959.	0.2	0
8	Cardiovascular Proteomics: A Post Hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist vs GnRH Agonist among Men with Advanced Prostate Cancer. Journal of Urology, 2021, 206, 952-959.	0.2	5
9	Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study. Nutrients, 2021, 13, 4295.	1.7	11
10	Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations. European Urology Focus, 2020, 6, 212-214.	1.6	9
11	Tubeless supra ostal percutaneous nephrolithotomy is associated with significantly less hydrothorax: a prospective randomized clinical study. BJU International, 2020, 125, 276-283.	1.3	4
12	Tandem Ureteral Stents for Malignant Ureteral Obstruction. Journal of Endourology, 2020, 34, 222-226.	1.1	15
13	Changes in Urology After the First Wave of the COVID-19 Pandemic. European Urology Focus, 2020, 7, 659-661.	1.6	12
14	Patients treated for uric acid stones reoccur more often and within a shorter interval in comparison to patients treated for calcium stones. Canadian Urological Association Journal, 2020, 14, E555-E559.	0.3	4
15	3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial. Carcinogenesis, 2020, 41, 1395-1401.	1.3	10
16	A noninferiority within-person study comparing the accuracy of transperineal to transrectal MRI–US fusion biopsy for prostate-cancer detection. Prostate Cancer and Prostatic Diseases, 2020, 23, 449-456.	2.0	17
17	3,3'-Diindolylmethane (DIM): A nutritional intervention and its impact on breast density in healthy BRCA carriers compared to non-treated carriers—A prospective clinical trial Journal of Clinical Oncology, 2020, 38, 1556-1556.	0.8	0
18	Short-Term Outcomes of Active Surveillance for Low Risk Prostate Cancer among Men with Germline DNA Repair Gene Mutations. Journal of Urology, 2020, 204, 707-713.	0.2	13

DAVID MARGEL

#	Article	IF	CITATIONS
19	Reply by Authors. Journal of Urology, 2020, 204, 713-713.	0.2	1
20	Re: Optimizing Patient's Selection for Prostate Biopsy: A Single Institution Experience with Multi-parametric MRI and the 4Kscore Test for the Detection of Aggressive Prostate Cancer. European Urology, 2019, 76, 535-536.	0.9	1
21	Characterizing the learning curve of MRI-US fusion prostate biopsies. Prostate Cancer and Prostatic Diseases, 2019, 22, 546-551.	2.0	37
22	Long-Term Adherence to Medications in Secondary Prevention of Urinary Tract Stones. Journal of Endourology, 2019, 33, 469-474.	1.1	11
23	Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease. Journal of Urology, 2019, 202, 1199-1208.	0.2	98
24	Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and antagonist among patients with advanced prostate cancer Journal of Clinical Oncology, 2019, 37, 5015-5015.	0.8	2
25	Effect of pectasol-c modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in non- metastatic biochemically relapsed prostate cancer (BRPC) patients (pts): Primary outcome analysis of a prospective phase II study Journal of Clinical Oncology, 2019, 37, e16609-e16609.	0.8	8
26	Vascular endothelium function among male carriers of BRCA 1&2 germline mutation. Oncotarget, 2019, 10, 5041-5051.	0.8	2
27	Reply By Authors. Journal of Urology, 2019, 202, 1208-1208.	0.2	0
28	Malignant Abnormalities in Male <i>BRCA</i> Mutation Carriers. JAMA Oncology, 2018, 4, 872.	3.4	17
29	Urinary Tract Infections After Urinary Diversion—Different Occurrence Patterns in Patients With Ileal Conduit and Orthotopic Neobladder. Urology, 2018, 116, 87-92.	0.5	18
30	Assessment of Needle Tip Deflection During Transrectal Guided Prostate Biopsy: Implications for Targeted Biopsies. Journal of Endourology, 2018, 32, 252-256.	1.1	21
31	A Novel Technique to Improve the Processing of Minute Ureteroscopic Biopsies. Pathology and Oncology Research, 2018, 24, 89-94.	0.9	2
32	Transplant Kidney Retrograde Ureteral Stent Placement and Exchange: Overcoming the Challenge. Urology, 2018, 111, 220-224.	0.5	10
33	Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-Guérin immunotherapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 531.e9-531.e17.	0.8	14
34	Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer. Urology, 2018, 118, 107-113.	0.5	16
35	Reply by the Authors. Urology, 2018, 115, 193.	0.5	0
36	Author Reply. Urology, 2018, 118, 112-113.	0.5	0

DAVID MARGEL

#	Article	IF	CITATIONS
37	Premature ovarian aging in <i>BRCA</i> carriers: a prototype of systemic precocious aging?. Oncotarget, 2018, 9, 15931-15941.	0.8	32
38	Effect of pectasol-c modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in non-metastatic biochemically relapsed prostate cancer (BRPC) patients (pts): Results of a prospective phase II study Journal of Clinical Oncology, 2018, 36, 14-14.	0.8	1
39	Lower Urinary Tract Symptoms and Benign Prostate Hyperplasia Features Among Male BRCA Mutation Carriers. Urology, 2017, 108, 71-75.	0.5	1
40	Nitric oxide charged catheters as a potential strategy for prevention of hospital acquired infections. PLoS ONE, 2017, 12, e0174443.	1.1	19
41	Effect of PectaSol-C modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in patients (pts) with nonmetastatic, biochemically relapsed prostate cancer (BRPC): Results of the interim analysis of a prospective phase II study Journal of Clinical Oncology, 2017, 35, e16588-e16588.	0.8	Ο
42	Is there a difference in testosterone levels and its regulators in men carrying BRCA mutations?. Oncotarget, 2017, 8, 103843-103850.	0.8	3
43	Nitric Oxide Charged Catheters as a Potential Strategy for Prevention of Hospital Acquired Infections. Open Forum Infectious Diseases, 2016, 3, .	0.4	1
44	Premature ovarian aging in <i>BRCA</i> carriers: ls it a prototype of systemic precocious aging?. Journal of Clinical Oncology, 2016, 34, e13016-e13016.	0.8	0
45	Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis. Canadian Urological Association Journal, 2015, 9, 14.	0.3	5
46	Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non–muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 67.e1-67.e7.	0.8	78
47	Advances in the treatment of testicular cancer. Translational Andrology and Urology, 2015, 4, 381-90.	0.6	16
48	Oncotype-DX recurrence score distribution among breast cancer patients harboring a germline mutation in the BRCA1/2 genes Journal of Clinical Oncology, 2015, 33, 564-564.	0.8	0
49	Is pathology necessary to predict mortality among men with prostate-cancer?. BMC Medical Informatics and Decision Making, 2014, 14, 114.	1.5	2
50	Obesity Is Associated With Larger Prostate Volume but not With Worse Urinary Symptoms: Analysis of a Large Multiethnic Cohort. Urology, 2014, 83, 81-87.	0.5	22
51	Usefulness of Bowel Sound Auscultation: A Prospective Evaluation. Journal of Surgical Education, 2014, 71, 768-773.	1.2	41
52	Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 975-980.	0.8	26
53	The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of Prostate Cancer Detection on Biopsy. Urology, 2014, 84, 1073-1080.	0.5	2
54	Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study. BMC Cancer, 2014, 14, 528.	1.1	5

DAVID MARGEL

#	Article	IF	CITATIONS
55	Reply to M.M.J. Zanders et al. Journal of Clinical Oncology, 2014, 32, 702-702.	0.8	2
56	Presence of detrusor muscle in bladder tumor specimens—predictors and effect on outcome as a measure of resection quality. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 40.e17-40.e22.	0.8	28
57	Metformin to Prevent Prostate Cancer: A Call to Unite. European Urology, 2014, 66, 1021-1022.	0.9	4
58	Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With Diabetes. Journal of Clinical Oncology, 2013, 31, 3069-3075.	0.8	240
59	Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates: A prospective cohort study Journal of Clinical Oncology, 2012, 30, 30-30.	0.8	1
60	Radiation Therapy for Prostate Cancer Increases the Risk of Subsequent Rectal Cancer. Annals of Surgery, 2011, 254, 947-950.	2.1	35
61	Stress Proteins and Cytokines are Urinary Biomarkers for Diagnosis and Staging of Bladder Cancer. European Urology, 2011, 59, 113-119.	0.9	57
62	Oral contraceptive use is associated with prostate cancer: an ecological study. BMJ Open, 2011, 1, e000311.e000311.	0.8	24
63	A novel algorithm to improve pathologic stage prediction of clinically organâ€confined muscleâ€invasive bladder cancer. Cancer, 2009, 115, 1459-1464.	2.0	22
64	Long-Term Follow-up of Patients with Stage T1 High-Grade Transitional Cell Carcinoma Managed by Bacille Calmette-GuA©rin Immunotherapy. Urology, 2007, 69, 78-82.	0.5	29
65	Predictors of Nocturia Quality of Life Before and Shortly After Prostatectomy. Urology, 2007, 70, 493-497.	0.5	47
66	Serum Tumor Markers May Predict Overall and Disease Specific Survival in Patients With Clinically Organ Confined Invasive Bladder Cancer. Journal of Urology, 2007, 178, 2297-2301.	0.2	18
67	Continuous positive airway pressure reduces nocturia in patients with obstructive sleep apnea. Urology, 2006, 67, 974-977.	0.5	114
68	Severe, but not mild, obstructive sleep apnea syndrome is associated with erectile dysfunction. Urology, 2004, 63, 545-549.	0.5	110